Autologous B-cell lymphoma idiotype (Id)

The autologous B-cell lymphoma idiotype refers to the unique, patient-specific variable region of the immunoglobulin (Ig) expressed on the surface of malignant B-cells. Because B-cell lymphomas arise from the clonal expansion of a single B-cell, every tumor cell in a given patient displays the same unique idiotype, making it a definitive tumor-specific antigen (Levy et al., 1982). In a physiological context, these idiotypes function as the antigen-binding site of the B-cell receptor, facilitating signal transduction and immune recognition. In oncology, the idiotype serves as a target for personalized active immunotherapy, typically through the production of patient-specific vaccines (Bendandi et al., 1999). These vaccines are designed to stimulate the patient's immune system to recognize and destroy the malignant clone while sparing healthy B-cells that do not share the specific idiotype. Despite the high specificity of this target, therapeutic challenges include the labor-intensive manufacturing process and the need for potent adjuvants to overcome the inherently low immunogenicity of these self-derived proteins (Schuster et al., 2011).

Other names

Tumor-specific idiotypeB-cell receptor idiotypeClonal immunoglobulin idiotypePatient-specific idiotypeSurface immunoglobulin idiotype

Active immunotherapy; Induction of patient-specific humoral and cellular immune responses against the unique variable region of the clonal B-cell receptor.